Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic
T-cell lymphoma.
PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients
with recurrent or refractory angioimmunoblastic T-cell lymphoma.